neurodegenerative disease Archives -

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson’s disease drug CVN424

After ph2 win, Cerevance preps pivotal trials of novel Parkinson’s drug

https://pharmaphorum.com/news/after-ph2-win-cerevance-preps-pivotal-trials-of-novel-parkinsons-drug/

Patients dismayed as FDA advisors narrowly reject Amylyx’ ALS drug

Phil Taylor Amylyx, amyotrophic lateral sclerosis, fda, neurodegenerative disease, neurology 0 Comment

By a narrow margin, an FDA advisory committee has voted against approval of Amylyx’ experimental medicine for amyotrophic

Patients dismayed as FDA advisors narrowly reject Amylyx’ ALS drug

https://pharmaphorum.com/news/patients-dismayed-as-fda-advisors-narrowly-reject-amylyx-als-drug/

Market Access/ News/ News

Amylyx slumps on non-committal FDA reviewer assessment of ALS drug

Phil Taylor Amylyx, amyotrophic lateral sclerosis, central nervous system, neurodegenerative disease 0 Comment

Shares in Amylyx Pharma slid today after the FDA published a less-than-enthusiastic assessment of its amyotrophic lateral sclerosis

Amylyx slumps on non-committal FDA reviewer assessment of ALS drug

https://pharmaphorum.com/news/amylyx-slumps-on-non-committal-fda-reviewer-assessment-of-als-drug/

News/ News/ R&D

Blow to Biogen as ALS hope tofersen flunks phase 3 trial

Phil Taylor ALS, Biogen, neurodegenerative disease, tofersen 0 Comment

Already struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback

Blow to Biogen as ALS hope tofersen flunks phase 3 trial

https://pharmaphorum.com/news/blow-to-biogen-as-als-hope-tofersen-flunks-phase-3-trial/

News/ News/ R&D

Bad news for Biohaven as verdiperstat flunks first phase 3 test

Phil Taylor Biohaven Pharmaceuticals, multiple system atrophy, neurodegenerative disease, rare disease, verdiperstat 0 Comment

Biohaven’s key pipeline drug verdiperstat has failed to have any Therapeutic effect in patients with the rare neurological

Bad news for Biohaven as verdiperstat flunks first phase 3 test

https://pharmaphorum.com/news/bad-news-for-biohaven-as-verdiperstat-flunks-first-phase-3-test/

News/ News/ R&D

AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial

Phil Taylor Alexion, amyotrophic lateral sclerosis, AstraZeneca, complement therapeutics, neurodegenerative disease, Soliris, UCB, Ultomiris, zilucoplan 0 Comment

It has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the new

AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial

https://pharmaphorum.com/news/azs-alexion-takeover-hits-a-snag-as-ultomiris-flunks-als-trial/

News/ News/ R&D

Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases

Phil Taylor Angelman Syndrome, Exicure, Huntington's disease, Ipsen, neurodegenerative disease, partnering, rare disease 0 Comment

Ipsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took

Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases

https://pharmaphorum.com/news/ipsen-forges-1bn-alliance-with-exicure-on-neurodegenerative-diseases/

Digital/ News/ News

Healx deploys its AI in hunt for Friedreich’s ataxia therapies

Phil Taylor artificial intelligence, ataxia, digital, digital health, Friedreich's ataxia, Healx, neurodegenerative disease, patient organisation 0 Comment

UK artificial intelligence specialist Healx has begun a partnership with two medical charities that aims to uncover new

Healx deploys its AI in hunt for Friedreich’s ataxia therapies

https://pharmaphorum.com/news/healx-deploys-its-ai-in-hunt-for-friedreichs-ataxia-therapies/

Digital/ News/ News

AI drug discovery firm Valence joins Parkinson’s disease push

Phil Taylor artificial intelligence, central nervous system, digital, digital health, drug discovery, neurodegenerative disease, Parkinson's disease, Valence Discovery 0 Comment

Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat

AI drug discovery firm Valence joins Parkinson’s disease push

https://pharmaphorum.com/news/ai-drug-discovery-firm-valence-joins-parkinsons-disease-push/

Trending

neurodegenerative disease

Login